natgillin/translations-raw huggingface dataset:
support the establishment of a European-wide sustainable clinical research network, which should speed up clinical studies on medicinal products, lower their costs, and improve coordination of clinical research;
podprla vzpostavitev evropske trajnostne klinično-raziskovalne mreže, ki naj bi pospešila klinične študije o zdravilih, zmanjšala njihove stroške in izboljšala usklajevanje kliničnih raziskav;
Antimicrobials: include antibiotics, antivirals, antifungals and antiprotozoals.
Antimikrobiki: vključujejo antibiotike, antivirusna zdravila, antimikotike in antiprotozoike.
To deal with the cross-border health threat of AMR, it is crucial to identify and share best practices and policies, so that a lack of action in one region or sector does not undermine progress made in others.
Pri obravnavanju čezmejnih nevarnosti za zdravje zaradi odpornosti proti antimikrobikom je ključno, da se opredelijo in delijo najboljše prakse in politike, da pomanjkanje ukrepanja v eni regiji ali sektorju ne bi oviralo napredka v drugih.
Drugs for bad bugs: confronting the challenges of antibacterial discovery Nature Reviews Drug Discovery 6, 29-40 (January 2007)]
[16: Payne et al. Drugs for bad bugs (Zdravila za slabe bacile): confronting the challenges of antibacterial discovery (spopadanje z izzivi odkritja antimikrobikov), Nature Reviews Drug Discovery 6, 29-40 (januar 2007).]
Despite all this, incidences of infections resistant to multidrug therapies and last-resort treatments have significantly increased in the EU in recent years.
Kljub vsemu temu pa se je incidenca okužb, odpornih proti zdravljenjem z več zdravili in zadnjim možnim oblikam zdravljenja, v zadnjih letih v EU bistveno povečala.
New economic models need to be developed to incentivise antimicrobial discovery and development while reconciling these incentives with responsible use.
Razviti je treba nove gospodarske modele, da bi se spodbudila odkrivanje in razvoj antimikrobikov ob sočasnem usklajevanju teh spodbud z odgovorno rabo.
Promote the prudent use of antimicrobials
Spodbujanje preudarne rabe antimikrobikov
The One Health approach also encompasses the environment, another link between humans and animals and likewise a potential source of new resistant microorganisms.
Pristop „eno zdravje" zajema tudi okolje, tj. še eno vez med ljudmi in živalmi, ki je prav tako tudi potencialni vir novih odpornih mikroorganizmov.
AMR already presents a serious social and economic burden.
Odpornost proti antimikrobikom že predstavlja resno družbeno in gospodarsko breme.
As one of the largest markets for agricultural products, the EU can play a major role in promoting its AMR-related standards, measures in food production, and standards on animal welfare, e.g. through its bilateral Free Trade Agreements (FTAs).
EU ima lahko kot eden največjih trgov kmetijskih proizvodov pomembno vlogo pri spodbujanju standardov, povezanih z odpornostjo proti antimikrobikom, ukrepov na področju proizvodnje živil in standardov glede dobrobiti živali, npr. prek dvostranskih sporazumov o prosti trgovini (SPT).
In line with this initiative, regular discussions among stakeholders will encourage them to develop and share their strategies against AMR.
V skladu s to pobudo jih bodo redne razprave med zainteresiranimi stranmi spodbudile, da razvijejo in izmenjujejo svoje strategije za boj zoper odpornost proti antimikrobikom.
Previously deadly diseases have become routine ailments, requiring little more than a brief treatment.
Nekoč smrtonosne bolezni so postale povsem običajne lažje zdravstvene težave, ki zahtevajo zgolj kratko zdravljenje.
Effective action against the rise of AMR will mitigate its negative impact on the economy and can therefore be considered a contribution to economic growth, to sustainable healthcare budgets by reducing healthcare costs and to a productive and healthy population.
Učinkovito ukrepanje zoper naraščajočo odpornost proti antimikrobikom bo ublažilo negativen vpliv na gospodarstvo, zato lahko šteje za prispevek h gospodarski rasti, vzdržnim proračunom za zdravstveno varstvo z zmanjševanjem stroškov zanj ter produktivnemu in zdravemu prebivalstvu.
This is a major cause for the inappropriate use of antimicrobials in humans and animals.
To je glavni vzrok za neustrezno rabo antimikrobikov pri ljudeh in živalih.
intensifying EU efforts worldwide to shape the global agenda on AMR and the related risks in an increasingly interconnected world.
okrepitev prizadevanj EU po vsem svetu za oblikovanje globalne agende o odpornosti proti antimikrobikom in povezanih tveganjih v medsebojno vedno bolj povezanemu svetu.
Resistance to antivirals, such as those used to treat HIV, is also increasing.
Povečuje se tudi odpornost proti antivirusnim zdravilom, kakršna se na primer uporabljajo za zdravljenje virusa HIV.
This makes AMR a complex epidemiological issue.
Zato je odpornost proti antimikrobikom kompleksno epidemiološko vprašanje.
[7: World Bank, 2016, ‘Drug-Resistant Infections: A Threat to Our Economic Future', Washington, DC.][8: http://www.un.org/sustainabledevelopment/sustainable-development-goals]
[7: Svetovna banka, 2016, „Drug-Resistant Infections: A Threat to Our Economic Future" (Okužbe, odporne proti zdravilom: grožnja naši gospodarski prihodnosti), Washington, DC.][8: http://www.un.org/sustainabledevelopment/sustainable-development-goals]
Other control measures, such as vaccination, could also reduce the occurrence and spread of certain diseases, limiting the need for antimicrobials.
Drugi ukrepi za obvladovanje, kot je cepljenje, bi tudi lahko zmanjšali pojavljanje in širjenje določenih bolezni, s tem pa omejili potrebo po antimikrobikih.
However, when any new antimicrobial treatment enters the market and is sold and used in large quantities, resistance can be expected to develop quickly.
A kadar na trg vstopi antimikrobik, ki se prodaja in uporablja v velikih količinah, je mogoče pričakovati hiter razvoj odpornosti.
Most of the actions can be done by adapting and reinforcing existing actions for a more integrated, comprehensive and effective approach to combating AMR.
Večino ukrepov je mogoče izvesti s prilagajanjem in okrepitvijo obstoječih ukrepov za doseganje bolj povezanega, celovitejšega in učinkovitejšega pristopa k boju zoper odpornost proti antimikrobikom.
Digital technologies for testing biomedical products and innovation in eHealth should also be scaled up, e.g. by supporting innovation procurement as well as supporting SMEs.
Nadgraditi bi bilo treba tudi digitalne tehnologije za testiranje biomedicinskih proizvodov in inovacij na področju e-zdravja, npr. s podpiranjem javnih naročil na področju inovacij in MSP.
Further support and assistance to EU Member States to address differences and foster cooperation, more efficient and coordinated research to improve knowledge and develop solutions, and a continued strong EU voice at global level, were also recommended.
Priporočena je bila tudi dodatna podpora in pomoč državam članicam EU za spopadanje z razlikami in spodbujanje sodelovanja, učinkovitejših in bolj usklajenih raziskav za izboljšanje znanja in razvoj rešitev ter nadaljnje odločno nastopanje EU na svetovni ravni.
continue to support research into the development of new effective preventive vaccines for humans and animals;
še naprej podpirala raziskave, usmerjene v razvoj novih učinkovitih preventivnih cepiv za ljudi in živali;
advocate EU standards and measures for tackling AMR in trade agreements and incorporate them into cooperative arrangements in trade agreements;
zagovarjala standarde in ukrepe EU za obravnavanje problema odpornosti proti antimikrobikom v trgovinskih sporazumih in jih vključevala v dogovore o sodelovanju v okviru trgovinskih sporazumov;
analyse the feasibility of setting up a global AMR clinical studies network in collaboration with G7 members;
analizirala izvedljivost vzpostavitve svetovne mreže kliničnih študij o odpornosti proti antimikrobikom v sodelovanju s članicami skupine G7;
The action plan will thus support the EU and its Member States in delivering innovative, effective and sustainable responses to AMR.
Akcijski načrt bo tako podprl EU in njene države članice pri oblikovanju inovativnih, učinkovitih in trajnostnih odzivov na odpornost proti antimikrobikom.
It is also crucial to prevent falsified or counterfeit antimicrobial products from entering the supply chain and harming humans or animals.
Ključno je tudi, da se prepreči vstop lažnih ali ponarejenih antimikrobikov v dobavno verigo in škoda, ki jo lahko povzročijo ljudem ali živalim.
Such actions, often referred to as ‘antimicrobial stewardship' actions, are in place in some sectors (e.g. EU guidelines for the prudent use of antimicrobials in veterinary medicine) but are not sufficiently developed for all situations in which antimicrobials are used.
Taki ukrepi, ki se pogosto imenujejo ukrepi za „usmerjanje rabe antimikrobikov", se v nekaterih sektorjih že izvajajo (npr. smernice EU za preudarno rabo antimikrobikov v veterinarski medicini), vendar niso zadosti razviti, da bi ustrezali v vseh primerih, v katerih se antimikrobiki uporabljajo.
[27: JA-04-2016 - Antimicrobial resistance and Health Care Associated Infections]
[27: JA-04-2016 - Odpornost proti antimikrobikom in okužbe, povezane z zdravstveno oskrbo.]
High levels of AMR in bacteria linked to numerous common infections (e.g. urinary tract infections, pneumonia, tuberculosis and gonorrhoea) have been observed in all WHO regions.
Visoke ravni odpornosti proti antimikrobikom pri bakterijah, povezanih s številnimi pogostimi okužbami (npr. okužbami urinarnega trakta, pljučnico, tuberkulozo in gonorejo), so zaznane v vseh regijah SZO.
promote international regulatory convergence between the EMA and other regulatory agencies such as the US Food and Drug Administration (FDA) and the Japan Pharmaceuticals and Medical Devices Agency (PMDA) on development plans for new promising antimicrobials.
spodbujala mednarodno približevanje zakonodaj med agencijo EMA in drugimi regulativnimi agencijami, kot sta Uprava za živila in zdravila Združenih držav (FDA) in japonska agencija za farmacevtske izdelke in medicinske pripomočke, v zvezi z načrti za razvoj novih obetavnih antimikrobikov.
Similarly, in the diagnostics sector, the development and uptake of novel diagnostics requires new models that take account of the relatively high price of diagnostics compared to the currently low price of antimicrobials.
Podobno v sektorju diagnostike razvoj in uporaba nove diagnostike zahteva nove modele, ki upoštevajo sorazmerno visoke cene diagnostike v primerjavi z antimikrobiki, ki so trenutno na voljo po nizki ceni.
maximise the use of data from existing monitoring, e.g. Watch List monitoring under the Water Framework Directive, to improve knowledge of the occurrence and spread of antimicrobials in the environment, including by using the Information Platform for Chemical Monitoring (IPCheM) to access relevant monitoring data;
čim bolj povečala uporabo podatkov iz obstoječih spremljanj, npr. spremljanja v okviru nadzornega seznama na podlagi okvirne direktive o vodah, da se izboljša znanje o pojavu in širjenju antimikrobikov v okolju, vključno z uporabo informacijske platforme za spremljanje kemikalij (IPCheM) za dostop do ustreznih podatkov o spremljanju;
encourage the uptake of diagnostics in medical and veterinary practice, e.g. through innovation procurement.
spodbujala uporabo diagnostike v medicinski in veterinarski praksi, npr. prek javnih naročil na področju inovacij.
The action plan will also strategically reinforce the research agenda on AMR and actively promote global action.
Obenem bo tudi strateško okrepil raziskovalni program o odpornosti proti antimikrobikom in aktivno spodbujal globalno ukrepanje.
There is scope for more collaboration and closer ties with these partners to build consensual activities, share experiences and align approaches, for the benefit of all sides.
Obstajajo možnosti za tesnejše sodelovanje in tesnejše vezi s temi partnerji, da bi se vzpostavila sporazumna dejanja, izmenjevale izkušnje in usklajevali pristopi v korist vseh udeleženih strani.
Improve knowledge on detection, effective infection control and surveillance
Izboljšanje znanja o odkrivanju ter učinkovitem obvladovanju in nadzoru okužb
adopt an EU strategic approach to pharmaceuticals in the environment;
sprejela strateški pristop EU k farmacevtskim snovem v okolju;
Such novel diagnostics are in the process of entering the market but more tests are needed to guide a more efficient use of existing antimicrobials in the human and animal health sectors.
Takšna nova diagnostika je v fazi vstopa na trg, vendar so potrebni dodatni testi za usmerjanje učinkovitejše rabe obstoječih antimikrobikov v sektorjih zdravja ljudi in zdravja živali.
Without effective action to reverse current trends, we could face a return to the pre-antibiotic era, with simple wounds and infections causing significant harm and even death and routine medical procedures becoming very high risk.
Brez učinkovitih ukrepov, ki bi zaustavili trenutne trende, bi nam lahko grozila vrnitev v čas pred obstojem antibiotikov: že manjše rane in okužbe bi povzročile veliko škodo in celo smrt, rutinski medicinski posegi pa bi pomenili zelo veliko tveganje.
To assist with and accelerate this collaboration, in early 2017 the Commission set up an AMR One Health network of government experts from the human health, animal health, and environmental sectors, as well as the EU scientific agencies working in the human and animal health sectors (ECDC, EMA, and EFSA).
Da bi pomagala pri tem sodelovanju in ga tudi spodbudila, je Komisija v začetku leta 2017 vzpostavila mrežo „eno zdravje" zoper odpornost proti antimikrobikom, ki jo sestavljajo vladni strokovnjaki iz sektorjev zdravja ljudi, zdravja živali in okolja ter znanstvenih agencij EU iz sektorjev zdravja ljudi in zdravja živali (ECDC, EMA in EFSA).
It takes into account the priorities set out in the WHO Global Action Plan on AMR, the JPIAMR and national action plans.
Upošteva prednostne naloge, ki so določene v globalnem akcijskem načrtu SZO o odpornosti proti antimikrobikom, programu JPIAMR in nacionalnih akcijskih načrtih.
Nevertheless, it continues to develop and spread across the world.
Kljub temu se odpornost proti antimikrobikom še naprej razvija in širi po vsem svetu.
EU involvement and collaboration with multilateral organisations such as the WHO, the OIE, the FAO and international forums should therefore be intensified in order to contribute to regional and global action on AMR, following the One Health approach.
Zaradi tega bi bilo treba okrepiti vključenost in sodelovanje EU z večstranskimi organizacijami, kot so SZO, OIE, FAO in mednarodni forumi, da bi se zagotovil prispevek regionalnemu in globalnemu ukrepanju zoper odpornost proti antimikrobikom v skladu s pristopom „eno zdravje".
Candidate countries and potential candidates benefiting from a pre-accession strategy have also made commitments regarding alignment and implementation of EU legislation related to AMR, as have the neighbouring countries to which the European Neighbourhood Policy (ENP) applies or who have an Association Agreement with the EU.
Države kandidatke in potencialne kandidatke, ki jim predpristopna strategija prinaša koristi, so prav tako dale zavezo uskladitvi in izvajanju zakonodaje EU v zvezi z odpornostjo proti antimikrobikom, kot so storile tudi sosednje države, za katere se uporablja evropska sosedska politika (ESP) ali ki so z EU sklenile pridružitveni sporazum.
The EU was quick to recognise the importance of tackling AMR, as the 2001 Community strategy against AMR shows.
EU je hitro prepoznala pomen obravnave odpornosti proti antimikrobikom, kar kaže strategija Skupnosti proti antimikrobni odpornosti iz leta 2001.
Shaping the global agenda
Oblikovanje globalne agende
This implies properly training of Member States' staff involved in official control activities and keeping them up to date on all aspects of EU legislation related to AMR in order to ensure that controls are carried out uniformly and objectively in all Member States.
To pomeni ustrezno usposabljanje osebja držav članic, ki so vključeni v dejavnosti uradnega nadzora, in redno seznanjanje tega osebja z vsemi vidiki zakonodaje EU o odpornosti proti antimikrobikom za zagotovitev enotnega in nepristranskega izvajanja nadzora v vseh državah članicah.
Many of the EU's domestic AMR policies (e.g. the ban on using antimicrobials as growth promoters in feed for food-producing animals) are already contributing to the achievement of international objectives against AMR.
Številne nacionalne politike EU o odpornosti proti antimikrobikom (npr. prepoved uporabe antimikrobikov kot spodbujevalcev rasti v krmi živali za proizvodnjo hrane) že prispevajo k doseganju mednarodnih ciljev v boju zoper odpornost proti antimikrobikom.
develop, with the support of the OECD, a model aimed at helping Member States to assess the economic burden of AMR imposes on people and to estimate the cost-effectiveness of their national policies to reduce it.
ob podpori OECD razvila model, katerega namen je pomagati državam članicam pri ocenjevanju gospodarskega bremena odpornosti proti antimikrobikom za ljudi ter ocenjevanju stroškovne učinkovitosti njihovih nacionalnih politik, usmerjenih v njeno zmanjšanje.
Special attention will be given to the WHO priority list of pathogens as well as to tuberculosis, HIV/AIDS, malaria and neglected infectious diseases.
Posebna pozornost bo namenjena prednostnemu seznamu patogenov SZO ter tuberkulozi, HIV/AIDS, malariji in zapostavljenim infekcijskim boleznim.
As the use of new antimicrobials needs to be restricted to minimise the risk of resistance development, the current business model results in a market failure for antimicrobials, and works against efforts to conserve effective antimicrobials.
Ker je treba rabo novih antimikrobikov omejiti, da bi se čim bolj zmanjšalo tveganje razvoja odpornosti, sedanji poslovni model povzroča tržno nepopolnost za antimikrobike in ovira prizadevanja za ohranitev učinkovitih antimikrobikov.
identify and assess under the Animal Health Law and with the support of the EFSA, resistant bacteria that cause transmissible animal diseases and, if necessary, develop harmonised rules for their surveillance;
v okviru pravil o zdravju živali in ob podpori agencije EFSA opredelila in ocenila odporne bakterije, ki povzročajo prenosljive bolezni živali, in po potrebi razvila usklajena pravila za njihovo spremljanje;
work towards continued high-level political attention and commitment to AMR action, including in the United Nations forums, the G7 and the G20;
prizadevala si bo za trajno politično pozornost na visoki ravni in zavezo ukrepanju zoper odpornost proti antimikrobikom, med drugim tudi na forumih Združenih narodov ter skupin G7 in G20;
AMR also threatens the achievement of several of the United Nations' sustainable development goals, particularly the targets for good health and well-being (goal 3).
Odpornost proti antimikrobikom ogroža tudi doseganje ciljev Združenih narodov na področju trajnostnega razvoja, zlasti ciljev, povezanih z zdravjem in dobrim počutjem (cilj 3).
promote the uptake of vaccination in humans as a public health measure to prevent infections and subsequent use of antimicrobials;
spodbujala uvajanje cepljenja pri ljudeh kot ukrepa v javnem zdravju, da bi se preprečile okužbe in nadaljnja raba antimikrobikov;
Further actions may also be considered to ensure a level playing field between EU producers and EU trading partners, e.g. so that efforts made by EU farmers are not compromised by the non-prudent use of antimicrobials in EU trading partners.
Lahko bi se preučila možnost za nadaljnje ukrepanje, da se zagotovijo enaki konkurenčni pogoji za proizvajalce EU in trgovinske partnerje EU, npr. tako, da se prizadevanja kmetov EU ne ogrozijo z nepreudarno rabo antimikrobikov pri trgovinskih partnerjih EU.
support SMEs in their R&D efforts towards innovative and/or alternative therapeutic approaches for the treatment or prevention of bacterial infections, together with the EMA;
podpirala MSP v njihovih prizadevanjih na področju RR, usmerjenih v inovativne in/ali alternativne terapevtske pristope za zdravljenje ali preprečevanje bakterijskih okužb, skupaj z agencijo EMA;
support research and innovation to promote the use of digital technologies supporting the development of new therapeutics and alternatives.
podpirala raziskave in inovacije, da bi spodbudila uporabo digitalnih tehnologij, ki podpirajo razvoj novih metod zdravljenja in alternativ.
This Communication provides a framework for future actions against AMR and aims to make the best possible use of the EU legal framework and policy instruments, focusing on the real added value the EU can bring to the fight against AMR.
To sporočilo določa okvir za prihodnje ukrepe za boj zoper odpornost proti antimikrobikom in si prizadeva doseči najboljšo možno uporabo pravnega okvira EU in instrumentov politike z usmerjenostjo v resnično dodano vrednost, ki jo EU lahko prispeva k boju zoper odpornost proti antimikrobikom.
advise Member States on the possibility to use the Structural Reform Support Service (SRSS) funding to Member States for designing and implementing policies against AMR.
svetovala državam članicam o možnosti uporabe sredstev podporne službe za strukturne reforme (SRSS) v državah članicah za oblikovanje in izvajanje politik boja zoper odpornost proti antimikrobikom.
Its overarching goal is to preserve the possibility of effective treatment of infections in humans and animals.
Njegov krovni cilj je ohraniti možnost učinkovitega zdravljenja okužb pri ljudeh in živalih.
Global efforts include the 2016 United Nations Political Declaration on AMR and the 2015 WHO Global Action Plan on AMR, which was subsequently adopted by the World Animal Health Organisation (OIE) and the Food and Agriculture Organization (FAO).
Svetovna prizadevanja vključujejo politično deklaracijo Združenih narodov iz leta 2016 o odpornosti proti antimikrobikom in globalni akcijski načrt SZO za leto 2015 o odpornosti proti antimikrobikom, ki sta ga naknadno sprejela Svetovna organizacija za zdravje živali (OIE) ter Organizacija za prehrano in kmetijstvo (FAO).
continue to contribute to reducing AMR in least developed countries through infectious disease programmes such as the Global Alliance for Vaccines and Immunisations (GAVI);
še naprej prispevala k zmanjševanju odpornosti proti antimikrobikom v najmanj razvitih državah prek programov za infekcijske bolezni, kot je Svetovno zvezo za cepiva in imunizacijo (GAVI);
Cooperation with industry is also crucial to promote the development of other promising alternatives to antimicrobials and to address reduced availability issues, including antimicrobial withdrawals from the market that may lead to antimicrobial shortages and inadequate replacement treatments.
Sodelovanje z industrijo je prav tako ključnega pomena za spodbujanje razvoja drugih obetavnih alternativ antimikrobikom in obravnavo vprašanj, povezanih z manjšo dostopnostjo, vključno z umiki antimikrobikov s trga, ki lahko pripeljejo do njihovega pomanjkanja in neustreznih nadomestnih zdravljenj.
engage with major global players and strategic countries (e.g. Brazil, China, India), contributing towards achieving objectives of the WHO Global Action Plan on AMR by sharing experiences, advocating best practices and thus stimulating actions outside the EU;
sodelovala z glavnimi svetovnimi akterji in strateškimi državami (npr. Brazilijo, Kitajsko, Indijo) in tako prispevala k doseganju ciljev globalnega akcijskega načrta SZO o odpornosti proti antimikrobikom z izmenjavo izkušenj, zagovarjanjem dobrih praks in spodbujanjem ukrepov zunaj EU;
AMR has also been addressed in the G7 and G20 forums.
Odpornost proti antimikrobikom je bila tudi predmet razprave na srečanjih skupin G7 in G20.